Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30868397 | 0.96 | ALDH1A1 (0.51) | ALDH1A1LMNACHEK1SIRT6TDP1 | |
| SCHEMBL6177383 | 0.90 | PDGFRB (0.46) | ALDH1A1LMNATDP1ACMSDPDGFRB | |
| SCHEMBL309803 | 0.81 | CHEK1 (0.46) | ALDH1A1LMNACHEK1SIRT6TDP1 | |
| SCHEMBL2208088 | 0.80 | ADRA2A (0.46) | ALDH1A1LMNACHEK1SIRT6TDP1 | |
| SCHEMBL522135 | 0.80 | QDPR (0.62) | ALDH1A1LMNACHEK1SIRT6 | |
| SCHEMBL13736939 | 0.80 | TDP1 (0.47) | ALDH1A1LMNASIRT6TDP1ACMSD | |
| SCHEMBL11224598 | 0.80 | CHEK1 (0.61) | ALDH1A1LMNACHEK1SIRT6TDP1 | |
| SCHEMBL25447049 | 0.80 | MAPT (0.49) | ALDH1A1ACMSDMAPTNPC1RAB9A | |
| SCHEMBL15993325 | 0.79 | QDPR (0.63) | ALDH1A1LMNACHEK1SIRT6MAPT | |
| SCHEMBL2201835 | 0.79 | SIRT6 (0.53) | ALDH1A1LMNACHEK1SIRT6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456202-B1 | BENZOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-6734179-B2 | SULFUR COMPOUNDS SUCH AS 4-FLUORO-N-(4-METHOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YL) -BENZAMIDE, USED AS PREFERENTIAL ADENOSINE RECEPTOR LIGANDS FOR THE PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-05-11 | — | — | US | disclosed |
| US-20030144288-A1 | Benzothiazoles | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144288-A1 | Benzothiazoles | ADORA2A, ADORA1, ADORA2B | ALDH1A1 89/4885LMNA 3584/4885CHEK1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.